Introduction
Recent advances in organ transplantation have been marked, and are mostly attributable to advances in transplantation techniques and immunosuppressants. To prevent organ rejection, lifelong use of immunosuppressants is essential for patients who undergo organ transplantation, and only a small proportion of these patients are weaned off immunosuppressants after a long period of time [1] . Cyclosporin A and FK506 are two common immunosuppressants that are clinically used today. The results of past studies have shown that the immunosuppressive effects of these agents are based on the inhibition of T-cell differentiation and proliferation. These agents bind to immunophilin (cyclophilin A and FK506-binding protein [FKBP] ), and the resulting complex suppresses the activity of calcineurin, which is a calmodulin-dependent protein phosphatase. Consequently, the production of cytokines, including interleukin-2 (IL-2), by sensitized T cells, and the subsequent T-cell activation, is suppressed [2, 3] . However, cyclosporin A and FK506 not only suppress the immune system but also induce many adverse reactions, including nephropathy [4] [5] [6] , and this can lead to the onset of osteoporosis following organ transplantation [7, 8] .
Bones are constantly being renewed through osteoblast-induced bone formation and osteoclastinduced bone resorption. Osteoporosis is characterized by an increase in bone resorption and a decrease in bone formation. Following the transplantation of an organ such as the liver, heart, or kidney, patients occasionally develop severe osteoporosis. This adverse reaction is recognized as a clinically important problem, and there have been reports on onset factors, risk factors, and prevention [9] [10] [11] [12] . However, because various factors are involved in the onset of osteoporosis following organ transplantation, no general consensus has been reached. Numerous studies in rats have been conducted Abstract After organ transplantation, severe osteoporosis is occasionally seen, and the use of immunosuppressants is thought to be one of the causes of such osteoporosis. In the present study, we investigated the effects of FK506 monotherapy on bones and determined the mechanism of onset of osteoporosis, both by assessing chronological changes in bone metabolism and by identifying factors that facilitate bone resorption. In 8-week-old male Sprague-Dawley rats, FK506 (1 mg/kg) was injected intraperitoneally every day for 5 weeks (FK506-treated group), and for comparison, physiological saline was administered in the same manner in a control group of rats. Serum and urine samples were collected at weeks 0, 1, 3, and 5 of administration. The femur and tibia were collected within 24 h of the final administration. When compared to the control group, findings on three-dimensional micro-computed tomography of the femur for the FK506-treated group showed a significant decrease in trabecular bone volume. The level of serum osteocalcin in the FK506-treated group at week 1 of administration was significantly higher than the control. Throughout the administration period, the sum of urinary pyridinoline (PYD) and deoxypyridinoline (Dpd) was significantly higher in the FK506-treated group. Of the various bone resorption factors tested, the level of serum parathyroid hormone (PTH) in the FK506-treated group was significantly higher than the control at week 3 of administration. The results of the present study confirmed that FK506 monotherapy in rats induced high-turnover osteoporosis. Soon after the start of FK506 administration, bone formation and resorption were elevated, and PTH appeared to have been involved in the maintenance of the elevated bone resorption.
to investigate the effects of cyclosporin A or FK506 monotherapy on bones, and it has been clarified that cyclosporin A or FK506 monotherapy causes osteoporosis [13] [14] [15] [16] [17] . The results of studies on bone morphology, blood biochemistry, and histology have shown that the osteoporosis associated with continuous immunosuppressant administration is attributable to increased bone resorption caused by an increase in the number of osteoclasts. We also reported that when FK506 was continuously administered to rats for a sufficient length of time, osteoporosis could be induced. Furthermore, we assessed bone morphology using soft X-rays and micro-three-dimensional (3D) computed tomography (CT), and revealed that, histologically, osteoporosis was attributable to an increase in the number of osteoclasts [18] . From the viewpoint of bone formation, levels of serum osteocalcin have been measured, but the focus of osteoporosis studies has largely been on bone resorption, and there has not been a study of the cause of the osteoporosis associated with FK506 administration based on bone formation and resorption. Also, none of the studies have followed rats with FK506-induced osteoporosis for periods as long as 5 weeks and analyzed the general kinetics.
In recent years, the usefulness of bone metabolism markers in assessing the activities of osteoblasts and osteoclasts has been reported, and these markers have often been used to assess the disease state of osteoporosis, select drugs, and evaluate therapy efficacy. With bone metabolism markers, both bone formation and resorption can be assessed, and, because the measurement of these bone metabolism markers is a noninvasive procedure, their levels can be measured frequently in order to determine chronological changes. It is clinically useful to ascertain the chronological changes in osteoblast and osteoclast activities when we wish to identify the mechanism of onset of osteoporosis associated with organ transplantation. In the present study, in an attempt to identify both the cause of osteoporosis following organ transplantation and a means to prevent it, we conducted an experimental study by continuously administering FK506 to rats. In the 5-week administration period, we were able to confirm the onset of osteoporosis, clarify the bone dynamics, in terms of bone formation and resorption, using bone metabolism markers, and identify the cause of osteoporosis by analyzing various data.
Materials and methods

Animal procedures
Twelve 8-week-old male Sprague-Dawley rats (Japan SLC, Shizuoka, Japan), each weighing approximately 267 Ϯ 6.6 g, were used in this study. All rats were housed under similar conditions, at 21°C, under a 12-h light/ 12-h dark cycle and maintained on a diet of CRF-1 (Oriental Yeast, Tokyo, Japan), containing 1.27% calcium, 0.84% phosphorus, and 0.25% magnesium, and tap water ad libitum.
Drugs
Prograf (Fujisawa Pharmaceutical, Osaka, Japan), a solution containing 5 mg FK506/ml, was diluted in physiological saline to obtain a final concentration of 1 mg/ml.
Experimental protocols
After acclimatization for a week, rats were randomly divided into two groups and were intraperitoneally injected with either FK506, at a dose of 1 mg/kg per day (FK506-treated group; n ϭ 7) or physiological saline (control group; n ϭ 5) for the duration of the 5-week experiment. All rats were weighed at weekly intervals and bled at weeks 0, 1, 3, and 5, under diethyl ether anesthesia (Wako Pure Chemical Industries, Osaka, Japan). Blood was collected by subclavian venous puncture, except in week 5, when samples were obtained from the abdominal aorta at the time the animals were killed. Blood samples were centrifuged and the serum stored at Ϫ80°C until assayed. Urine was collected in metabolic cages, during an 18-h period, overnight in weeks 0, 1, 3, and 5 after the start of the experiment. Urine samples were centrifuged and stored at Ϫ80°C until assayed. While they were under diethyl ether anesthesia, all rats were killed in week 5, 24 h after the last administration of either FK506 or physiological saline. Femurs and tibiae were removed from each rat and were used for analysis.
Analysis of bone weights and evaluation of femurs by 3D-micro CT
The left femurs and tibiae were used to determine dry (dehydrated) weights after being dried in a convection oven at 60°C for 10 days. The right femurs were used for 3D reconstruction by means of micro-CT (µCT 20; Hitachi Medical, Tokyo, Japan). Each specimen was held in a cylindrical sample holder and then 200 slices were analyzed within the area determined through a pre-scout view. Each acquired image was reconstructed to produce a 3D image with an extended marching cube algorithm for 3D observation on display. The trabecular bone volume fraction (bone volume [BV] / tissue volume [TV] %) and trabecular separation (TbS) were calculated with an MCT system software package (Hitachi Medical, Tokyo, Japan).
Blood analysis
Serum samples were analyzed for calcium, osteocalcin, parathyroid hormone (PTH), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6). Total calcium in serum was determined with a Wako Calcium C diagnostic kit (Wako Pure Chemical Industries, Osaka, Japan). This kit is based on the o-cresolphthalein complexon color development method. Serum osteocalcin was measured by an enzyme-linked immunosorbent assay (ELISA), using a commercially available kit specific for rat osteocalcin (Biomedical Technologies, Stoughton, IN, USA). Serum immunoreactive PTH was measured with a rat-specific ELISA kit reacting with intact PTH (Immutopics, San Clemente, CA, USA). Serum TNF-α was assayed using a commercially available rat ELISA kit (Quantikine M; R&D Systems, Minneapolis, MN, USA). IL-6 in serum was measured using a commercially available rat-specific ELISA kit (Endogen, Woburn, MA, USA).
Urine analysis
Urine samples were analyzed for calcium, creatinine, and the sum of pyridinoline (PYD) and deoxypyridinoline (Dpd). Total calcium in urine was determined with the same kit as that used for serum calcium. Creatinine was determined with a Wako creatinine test kit (Wako Pure Chemical Industries). PYD and Dpd in urine were assayed using a commercially available Metra PYD kit (Quidel, San Diego, CA, USA). The sum of the PYD and Dpd level of each sample was expressed as the value corrected by creatinine concentration.
Statistical analysis
Data values were expressed as means Ϯ SEM. Statistical evaluations of the effect of FK506 on the various parameters measured were made by analysis of variance with Student's t-test and Welch's t-test. P values of less than 0.05 were considered significant for all statistical analyses.
Results
Body weight
Body weight increased in all animals for the duration of the 5-week experiment. The FK506-treated group showed a significantly lower weight than the control group by the first week (P Ͻ 0.005) and continued to do so until the end of the experiment (Fig. 1) .
Analysis of bone weights and micro-3D CT observations
Compared with the control group, the bone ash weights of both femur and tibia for the FK506-treated group were decreased (Ϫ88.7% and Ϫ91.4%, respectively), but there were no significant differences when the value was corrected by body weight. The 3D micro-CT analysis showed the microstructure of trabecular bone in the rat femur. In the FK506-treated group, the trabeculae were narrow and the bone marrow cavity was wide in some parts (Fig. 2) . BV/TV was significantly decreased in the FK-506 treated group (control group, 69.24 Ϯ 1.69%; FK506-treated group, 50.32 Ϯ 1.50%; P Ͻ 0.001). The difference was significant for TbS between the two groups (control group, 0.0343 Ϯ 0.0064 µm; FK506-treated group, 0.0487 Ϯ 0.0015 µm; P Ͻ 0.01).
Calcium levels
Although the level of serum calcium remained mostly within the normal range for both groups, there was a significant increase in the level of urinary calcium for the FK506-treated group, compared with the control group, from week 1 of administration (Fig. 3) . Figure 4 shows the effect of FK506 administration on the biochemical markers. Serum osteocalcin levels were measured to investigate the activity of bone formation, and the sum of PYD and Dpd levels was measured for determining bone resorption. There was a trend in the Fig. 1 . Time course of body weight. Body weight was significantly decreased from the first week in the FK506-treated group compared with the control group. All values are means Ϯ SEM.*P Ͻ 0.05; **P Ͻ 0.005; ***P Ͻ 0.0005 compared with the control group control group for decreased serum osteocalcin levels throughout the 5-week experiment, compared with the baseline level. In the FK506-treated group, however, serum osteocalcin increased in the first week and then decreased. The level of serum osteocalcin for the FK506-treated group at week 1 of administration was significantly higher (P Ͻ 0.005) than that for the control group, but there was no significant difference after that. Urinary PYD and Dpd levels in the control group also showed a trend to decrease for the length of the study, compared with the baseline level. By contrast, PYD and Dpd levels in the FK506-treated group showed an increase over time. Throughout the administration period, the sum of urinary PYD and Dpd levels was significantly higher for the FK506-treated group than for controls.
Biochemical markers
Levels of PTH, TNF-α, and IL-6 in serum
Of the various bone resorption factors, the level of serum PTH for the FK506-treated group was significantly higher than that for the control group at week 3 of administration (Fig. 5 ). There were no significant differences between the two groups in the levels of TNF-α and IL-6 (data not shown). Fig. 4 . Effects of FK506 on biochemical markers. a Serum osteocalcin was significantly increased in the first week in the FK506-treated group compared to the control group. b Throughout the administration period, the sum of urinary pyridinoline (PYD) and deoxypyridinoline (Dpd) levels for the FK506-treated group was significantly higher than that in the controls. All values are means Ϯ SEM. *P Ͻ 0.05; **P Ͻ 0.005 vs control group. Symbols, as in Fig. 1 . Cr, creatinine Fig. 3 . Effect of FK506 on calcium levels. a Calcium levels in serum had no differences between the two groups at any time points. b Calcium levels in urine were significantly increased from the first week in the FK506-treated group compared with the control group. All values are means Ϯ SEM. *P Ͻ 0.05; **P Ͻ 0.005 vs control group. Symbols, as in Fig. 1 
Discussion
Osteoporosis following organ transplantation markedly lowers the quality of life (QOL) of patients, and as a result, osteoporosis is an important clinical issue because the use of certain drugs needs to be restricted.
There have been various studies on the cause of osteoporosis after organ transplantation, and it has been suggested that immunosuppressants may play some role [19, 20] . However, it has been difficult to elucidate the precise cause of the osteoporosis, because numerous factors are involved. There have been numerous animal studies using rats that have investigated the effects of immunosuppressant monotherapy on bones, and these have shown that cyclosporin A and FK506 induce osteoporosis when administered continuously for a sufficient period of time. Nonetheless, the results of animal studies [21] [22] [23] and clinical studies [24, 25] have clarified that FK506 is an effective immunosuppressant with fewer adverse reactions when compared to cyclosporin A. In addition, when compared to cyclosporin A, the effects of FK506 on bones are less [26] . The results of a study using rats showed that, while the incidence of osteoporosis for continuous cyclosporin A administration was significantly higher than that for the control group, there was no marked difference between the incidence of these symptoms in rats with continuous FK506 administration and the controls, thus proving the usefulness of FK506 [27] .
In the present study, in order to clarify the effects of FK506 administration on bones, this drug was administered intraperitoneally every day for 5 weeks. When compared to the control group (physiological saline), 3D bone measurement showed a marked decrease in bone volume for the FK506-treated group. Interestingly, the concentration of FK506 used in the present study is comparable to that associated with organ transplantation in studies using rats. According to the past studies, the minimal effective dose of FK506 in rats is 1.0 mg/kg per day, and a dose of 3.2 mg/kg per day is commonly used for experiments on organ transplantation in rats [22, 23, 28] . These figures are for oral administration; however, 1.0 mg/kg per day intraperitoneal administration of FK506 is preferable, and is equivalent to oral administration in terms of blood concentration. In other words, the results of the present study suggest that the FK506 doses that are routinely used in clinical settings can easily induce osteoporosis.
According to previous reports, continuous administration of an immunosuppressant induces highturnover osteoporosis in rats, but cyclosporin A and FK506 may have different onset mechanisms [17, 29] . In the present study, using bone metabolism markers that are widely used in the clinical setting, chronological changes in bone dynamics were investigated in terms of osteoblast and osteoclast activity. The results showed that the level of serum osteocalcin for the FK506-treated group at week 1 of administration was significantly higher than that for the control group, but there was no marked difference after that. As there are limitations in the use of bone formation markers, including bone-specific and total alkaline phosphatases, these parameters were not measured in this study. There is no established ELISA method for measuring bone alkaline phosphatase levels. Even when the levels of total alkaline phosphatase are determined, measurements are influenced not only by bone disease but also by changes in the liver, small intestine, and other organs affected by FK506. Because accurate measurements could not be obtained, only serum osteocalcin was measured to assess bone formation. The sum of PYD and Dpd for the FK506-treated group at week 1 of administration was significantly higher than that for the control group, and remained so until the end of the study. Therefore, we deduced that FK506 administration caused highturnover osteoporosis as follows: an increase in bone resorption caused an increase in osteoblast activity, thus elevating bone formation, but the rate of bone resorption continued to increase, and osteoporosis developed in the femur and tibia at 5 weeks.
The results of the present study suggest that PTH is closely involved with continuously elevated bone resorption. Bone remodeling is regulated by various factors, and both TNF-α and IL-6 are key factors involved in increased bone resorption [30] . In recent years, PTH has been developed as an agent to facilitate bone formation, but it can also act as a bone-resorption factor by indirectly inducing osteoclasts via osteoblasts. In order to elucidate the onset mechanism of osteoporosis, levels of serum PTH, TNF-α, and IL-6 were measured, and the results showed that, while there was no significant difference in TNF-α and IL-6 between the control and FK506-treated groups, the level of PTH for the FK506- Fig. 5 . Effect of FK506 on serum parathyroid hormone (PTH). Serum PTH was significantly increased at week 3 in the FK506-treated group compared with the control group. All values are means Ϯ SEM. *P Ͻ 0.05 compared with the control group. Symbols, as in Fig. 1 treated group was significantly higher than that for the control group at week 3 of administration. As was the case with the present study, Cvetkovic et al. [29] reported that there was an increase in the level of PTH 28 days after the start of FK506 administration, whereas the level of blood calcium for the FK506-treated group was lower than that for controls. In the present study, the level of serum calcium was within the normal range throughout the study period for both groups, but the level of urinary calcium for the FK506-treated group was significantly higher than that for the control group. When compared to the control group, the level of urinary creatinine for the FK506-treated group was significantly lower from week 3 of administration, and thus FK506 administration may induce nephropathy. As a result of this type of nephropathy, calcium resorption in the renal tubules would be insufficient, thus increasing the level of excreted calcium. Due to subsequent renal dysfunction, levels of blood calcium would decrease, and to compensate for this loss, the secretion of PTH, which mobilizes calcium in the blood, would be elevated. Therefore, secondary hyperparathyroidism may be involved as a background factor for the adverse reactions and osteoporosis associated with FK506 monotherapy.
The results of the present study clarified that osteoporosis can be induced by FK506 at doses that are regularly used in the clinical setting. Soon after the start of administration, osteoblast and osteoclast activities increase, and when administration is continued, an increase in PTH maintains the heightened bone resorption and exacerbates the osteoporosis. In the future, we plan to identify a means to prevent osteoporosis by clarifying the onset mechanisms for increased osteoblast and osteoclast activities following the start of FK506 administration.
